Results 111 to 120 of about 174,708 (252)

Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity. [PDF]

mBio, 2023
Marchitto L, Benlarbi M, Prévost J, Laumaea A, Descôteaux-Dinelle J, Medjahed H, Bourassa C, Gendron-Lepage G, Kirchhoff F, Sauter D, Hahn BH, Finzi A, Richard J.   +12 more
europepmc   +1 more source

Multifunctional Thiolated Hyaluronic Acid‐graft‐PEDOT Dressing With Antifouling, On‐Demand Drug Delivery and Electrical Stimulation for Wound Healing

Advanced Healthcare Materials, EarlyView.
A multifunctional P(EDOT‐co‐EDOT‐g‐THA) dressing acts as a dynamic biointerface integrating antifouling capability, on‐demand drug delivery, and electrical stimulation. It achieves electrochemically triggered thiolated hyaluronic acid (THA) release while modulating cellular responses for wound healing application.
Jingwen Yang, Jiwon Hong, Anthony Phillips, Bicheng Zhu, Jenny Malmstrom, Devon T. Bryant, Alireza Akbarinejad, Lisa I. Pilkington, Jadranka Travas‐Sejdic   +8 more
wiley   +1 more source

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity. [PDF]

Cell Rep, 2023
Laumaea A, Marchitto L, Ding S, Beaudoin-Bussières G, Prévost J, Gasser R, Chatterjee D, Gendron-Lepage G, Medjahed H, Chen HC, Smith AB, Ding H, Kappes JC, Hahn BH, Kirchhoff F, Richard J, Duerr R, Finzi A.   +17 more
europepmc   +1 more source

Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1

Advanced Healthcare Materials, EarlyView.
A bicistronic rAAV8 vector encoding Aflibercept (Afb) and COMP‐cAng1 simultaneously coordinates VEGF clearance and Tie2‐mediated vessel maturation. In a 3D angiogenesis‐on‐a‐chip model, rAAV8‐Afb/cAng1 effectively reverses pathological barrier breakdown under clinical disease‐mimicking challenges.
Bong‐Kyu Kim, Jaehong Min, Sang‐Hee Park, Subeen Shin, Sangbin Yu, Jeong‐Eun Park, Sujin Kim, Wooju Park, Jihoon Ko, Sunjong Kwon   +9 more
wiley   +1 more source

Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform. [PDF]

Sci Rep, 2022
Kang CE, Lee S, Ahn T, Seo DH, Ko BJ, Jung M, Lee J, Kim JY, Kim WT.   +8 more
europepmc   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. [PDF]

NPJ Vaccines, 2022
Park SY, Levin MJ, Canniff J, Johnson M, Schmid DS, Weinberg A.   +5 more
europepmc   +1 more source

Tumor‐Targeted Hyaluronic Acid/Tannic Acid‐Engineered Oxygen Nanogenerators With IR780 Payloads Enable Dual‐Mode Glutathione Depletion and Effective Singlet Oxygen Generation for Melanoma Treatment

Advanced Healthcare Materials, EarlyView.
A hyaluronic acid/tannic acid‐engineered Prussian blue oxygen nanogenerator loaded with IR780 is developed to enhance melanoma phototherapy. By integrating tumor targeting, oxygen self‐supply, and dual‐mode glutathione depletion, the nanoplatform effectively overcomes hypoxia and antioxidant defenses, potentiating synergistic photothermal/photodynamic ...
Chai‐How Hsu, I‐Ju Liu, Hsiang‐Yun Chih, Tsai‐Ching Hsu, Ju‐An Liang, Chia‐Wei Kuo, Bor‐Show Tzang, Wen‐Hsuan Chiang   +7 more
wiley   +1 more source

Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity. [PDF]

AAPS J
Guan J, Wang T, Tessier PM, Thurber GM.
europepmc   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

Advanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans, Abdulwahhab Khedr, Panagiotis G. Georgiou, Nehir Arik, Ozlem Sen, Steve P. Rannard, Tom O. McDonald, Christos Tapeinos   +7 more
wiley   +1 more source